Flourish: Early infant gut microbiome program for babies born by C-section
Official title: Flourish Study: A Randomized, Three-Arm Longitudinal Clinical Study of Microbiome-Guided Interventions in Cesarean-Born Infants
Run by Seeding Inc · NCT07333482 · Data updated 2026-11-12
This project tests whether microbiome analysis, education, and personalized recommendations can improve gut bacteria and reduce early immune-related markers in babies born by C-section aged 0–3 months.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 0 Months to 3 Months |
| Sex | All |
| Enrollment | 250 (estimated) |
| Sponsor | Seeding Inc Industry-sponsored |
| Locations | 1 site (Austin, Texas) |
| Status | Recruiting |
| Started | January 31, 2026 |
| Main results expected | June 2028 |
| Study ends | September 2028 |
| Registry record updated | February 24, 2026 |
| Trial ID | NCT07333482 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are singleton infants aged 0–3 months born by Cesarean at ≥36 weeks gestation who live in the United States and have not received probiotic supplements.
✕Probably not a fit
Infants with prior probiotic exposure, multiple births, preterm delivery under 36 weeks, or existing gastrointestinal or immune disorders are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Flourish enrolls infants aged 0–3 months delivered by Cesarean and randomizes them to a full intervention (microbiome reports, coaching, tailored recommendations, and educational materials), a limited intervention (simplified reports and basic recommendations), or a control that receives results after completion. Researchers collect stool samples and analyze microbiome composition and function to measure beneficial bacteria, C-section-associated signatures, opportunistic pathogens, HMO digestion potential, and short-chain fatty acid production. The interventions include personalized recommendations, consult calls, and an educational email series, with exclusion of infants given probiotic supplements, multiples, preterm under 36 weeks, or with certain gastrointestinal or immune conditions. Primary outcomes include shifts in microbiome composition and the prevalence of early atopic symptoms over the study period.
Why it matters
Potential benefit: If successful, the approach could help shift infants' gut microbiomes toward healthier profiles and reduce early signs of allergy or eczema.
How similar studies have gone: Previous research has shown some ability to modify early gut colonization and associations with allergy risk, but personalized microbiome coaching and tailored recommendations like these are relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Infants are qualified for this study if they are 0 to 3 months of age at time of enrollment. * Infants must have been delivered via Cesarean delivery (C-section), either scheduled or emergent. * Infants must have been at least 36 weeks gestation at time of delivery. * Infants and their caregivers must reside in the United States with a US mailing address. Exclusion Criteria: * Infants can not have been given probiotic supplements in their life at recruitment. This includes probiotic powder or supplements or formula with probiotic addition or multivitamin with probiotic addition. * Twin and multiple birth infants are not accepted in this study. * Infants cannot have the following existing health conditions: * Gastrointestinal conditions: Hirschsprung disease, eosinophilic gastrointestinal disorders (EGID) including eosinophilic esophagitis (EoE), necrotizing enterocolitis (NEC), short bowel syndrome (SBS) * Immune or auto-immune conditions: Severe Combined Immunodeficiency (SCID), human immunodeficiency virus (HIV)), excluding eczema and rashes * Congenital conditions: cleft lip or cleft palate, congenital heart disease, cerebral palsy, fragile X syndrome, down syndrome, spina bifida, cystic fibrosis, phenylketonuria (PKU), congenital hypothyroidism (CHT), galactosaemia) * Blood disorders (sickle cell disease, thalassemia, hemophilia) * Infant or any immediate family member has previously received results from an at-home microbiome stool test (excluding standard clinical diagnostic testing such as stool culture or pathogen testing)
Where it's running
-
Seeding Labs INC
Austin, Texas, United States Recruiting
Study contacts
- Principal investigator: Qian Yuan, MD — Massachusetts General Hospital
- Study coordinator: Kimberley Sukhum, PhD
- Email: hello@seedinglabs.co
- Phone: 512-827-9765
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
How exposure to heavy metals, nanoparticles, and emerging contaminants relates to allergic skin and systemic metal reactions
This project will test whether adults with allergic contact dermatitis or systemic metal allergies have different levels of heavy metals, nanoparticles, and related blood and urine markers compared with healthy adults.
-
Overnight Temperature Regulation to Test Gut Health, Inflammation, and Circadian Rhythms
This study tests whether two weeks of using the Eight Sleep Pod at night can improve gut bacteria balance, lower inflammation, and strengthen daily temperature and blood pressure rhythms in postmenopausal women and age-matched men with poor sleep.
-
Egg intake and gut health, HDL, and immune markers in adults
This study tests whether daily egg whites or whole eggs affect gut microbiome, HDL function, metabolism, and immune profiles in adults with a range of BMIs.
-
Tiny Tummies: Milk vs. Oat Milk for Toddlers
This 12‑month randomized study will test whether 12‑month‑old toddlers who drink daily cow’s milk dairy vs. oat milk dairy have better growth, sleep, neurocognitive outcomes, and gut microbiome by 24 months.
-
Probiotic supplementation to support gut health, immune response, and well-being in adults
In this 8-week study, healthy adults with mild to moderate stress will take a probiotic supplement or placebo daily to see if it affects gut barrier function, immune markers, and well-being.
-
Digital mindfulness app for teens with eczema
Teens with moderate to severe eczema try a digital mindfulness app to see if it helps control symptoms and improve quality of life.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.